Vivanza Biosciences Limited is a **BSE-listed** Indian enterprise currently undergoing a transformative strategic pivot. Historically focused on the pharmaceutical and healthcare sectors, the company is aggressively diversifying into high-growth industries including renewable energy, information technology, and advanced packaging. Headquartered in **Ahmedabad**, the company operates through a lean corporate structure supported by its 100% wholly-owned subsidiary, **Vivanza Lifesciences Private Limited**. --- ### **Strategic Pivot: Diversification & The "Main Object" Expansion** In **late 2025**, Vivanza received shareholder approval via **Special Resolution** to significantly broaden its **Memorandum of Association (MOA)**. This expansion allows the company to move beyond its traditional pharmaceutical roots into several new, high-growth verticals: * **Energy & Infrastructure:** Trading and manufacturing of **solar and renewable energy equipment**, power projects, and **EPC (Engineering, Procurement, and Construction)** turnkey projects. * **Technology & Digital Assets:** Development of **software**, **IT-enabled services (ITeS)**, **data centers**, **cloud facilities**, and **AI/drone information technology projects**. * **Advanced Manufacturing:** **Contract manufacturing**, assembling, and fabricating across multiple industrial sectors. * **Real Estate & Agro-Trading:** Engaging in **land development** and the processing/distribution of all types of **agro-based products**. To facilitate this expansion, the company’s borrowing limit was significantly increased in **July 2024** from **Rs. 20 Crore** to **Rs. 90 Crore**, providing the necessary financial leverage for large-scale project execution. --- ### **Core Pharmaceutical & Healthcare Operations** Despite its diversification, the pharmaceutical division remains the company's foundational revenue driver. The business model focuses on **R&D**, manufacturing, and the distribution of high-quality medicines. * **Market Focus:** A primary target is the **ROW (Rest of World)** market, with a specific emphasis on **African nations**. * **Turnkey Solutions:** Beyond product sales, the company executes **turnkey pharmaceutical units**, providing consultancy and engineering expertise for international healthcare infrastructure. * **Revenue Recognition:** Revenue is recognized at the point in time when **control is transferred** (delivery and customer acceptance). Contracts are structured without rights to **returns or refunds**, though a **standard warranty provision** is maintained for faulty goods. * **Credit Terms:** Operations are characterized by **short-term credit periods** without significant financing components. --- ### **Specialized Industrial Segments** Vivanza has integrated specialized divisions to capture value across the industrial supply chain: * **Films & Packaging:** This division manufactures **plastic polymer films (25 microns thickness)**, **PE/PP bags**, and **flexible packaging** tailored for the food, chemical, and fertilizer industries. * **Agro Division:** Focuses on **Agro Trading & Consultancy**, dealing in diverse agro-based commodities and providing technical advisory services. --- ### **Financial Structure & Capital Management** The company maintains a stable capital base but has seen a recent reduction in its reserves as it reallocates capital toward growth initiatives. | Metric | Value / Status | | :--- | :--- | | **Authorized Share Capital** | **Rs. 4,00,00,000** (4 Cr shares of Rs. 1 each) | | **Paid-up Share Capital** | **Rs. 4,00,00,000** (Fully Paid) | | **Share Split (March 2023)** | Sub-divided from **Rs. 10** to **Rs. 1** face value | | **Accounting Standard** | **Ind AS** (Effective April 1, 2017) | | **Dividend Status** | No dividend declared for FY **2023, 2024, or 2025** | **Liquidity Position (as of March 31, 2025):** The company manages total financial liabilities of **Rs. 931.05 Lakhs**. | Liability Type | 0-12 Months (Rs. Lakhs) | >12 Months (Rs. Lakhs) | Total (Rs. Lakhs) | | :--- | :--- | :--- | :--- | | Current Borrowings | **531.73** | - | **531.73** | | Trade Payables | **90.34** | **231.46** | **321.80** | | Non-current Borrowings | - | **77.52** | **77.52** | --- ### **Operational Strategy for Sustainable Growth** Vivanza employs four critical pillars to drive stakeholder value: 1. **Specialty Business:** Increasing the global market share of **technically complex products**. 2. **Compliance:** Maintaining rigorous adherence to **global cGMP (Current Good Manufacturing Practice)** regulatory standards. 3. **Cost Leadership:** Optimizing the manufacturing footprint and diversifying the supplier base to mitigate global supply chain disruptions. 4. **Business Development:** Utilizing **Joint Ventures** and **Technical Collaborations** to enter untapped markets across the global value chain. --- ### **Risk Profile & Mitigation Framework** The company operates under a formal **Risk Management Framework** overseen by an **Audit Committee**. **Financial & Regulatory Risks:** * **Non-Performing Assets (NPAs):** Historical loans and advances to third parties have been classified as **NPAs**. While income recognition has ceased, these remain an **Emphasis of Matter** in Auditor Reports. * **Section 186 Compliance:** Auditors have noted historical deviations from **Section 186(7) of the Companies Act, 2013**, specifically regarding non-interest-bearing loans to **Related Parties**. * **Deferred Expenses:** Approximately **₹3.66 lakhs** in preliminary and issue-related expenses are carried as assets; auditors suggest these should be written off to avoid understating expenses. **Market & Macro Risks:** * **Interest Rate Volatility:** The company uses **Floating Rate Borrowings** tied to the **MCLR**. Exposure has been trending downward: * **2023:** ₹257.71 Lakhs * **2024:** ₹220.66 Lakhs * **2025:** **₹187.38 Lakhs** * **Currency Risk:** As an exporter, the company is sensitive to exchange rate shifts and employs **hedging strategies** to protect margins. * **Credit Risk:** The company manages a **Trade Receivable** book of **Rs. 738.59 Lakhs**. While the **Expected Credit Loss (ECL)** is currently **0%**, a significant portion (**Rs. 653.39 Lakhs**) is aged more than six months, requiring close monitoring.